The Prime Minister and the Brazilian Vice President, Michel Temer were joined by double Olympic gold medal winner Mo Farah to urge a global drive to boost nutrition.
The two leaders hosted a high-level meeting bringing together representatives from international governments, charities and businesses at Downing Street on the day of the closing ceremony of the London Olympics. They urged the world to take decisive action before the 2016 Olympic Games in Rio to transform the life chances of millions of children by improving their nutrition.
Three new initiatives were announced on these areas, one of these is that some leading UK companies such as Unilever, Syngenta and GSK will work to find ways to make nutritious food available to poor families at prices they can afford.
The Guardian has reported thatGSK today marks its role as Official Laboratory Services Provider for the London 2012 Olympic and Paralympic Games by launching its first UK advertising campaign to celebrate the role that anti-doping science will play in helping ensure this summer’s Games are the cleanest possible.
The multimillion-pound ad campaign features a string of British athletes, including Marlon Devonish and Phillips Idowu to highlight its role running the anti-doping testing laboratory for the London Olympic games.
The London 2012 anti-doping laboratory, provided by GSK in partnership with the London Organising Committee for the Olympic and Paralympic Games (LOCOG) and King’s College London opened today and will be operational 24 hours a day, seven days a week. More tests will be carried out at the London 2012 lab, based at GSK’s Harlow site, than at any other Games with every medallist and up to 50 per cent of all competing athletes being tested.
PharmaTimeshave reported that GlaxoSmithKline andTheravance have reported positive data from four Phase III trials assessing a combination therapy for maintenance treatment of COPD, making the once-daily pill closer to a regulatory filing.
The clinical trials involved more than 4,000 patients, including two 24-week efficacy trials comparing a combination of the long-acting muscarinic antagonist (LAMA) umeclidinium bromide and the long-acting beta-agonist (LABA) vilanterol. The date showed statistically significant improvements when compared with placebo and the individual parts in both trials, which tested difference doses.
Darrell Baker, SVP Respiratory Portfolio Optimisation Leader at GSK said “We are very encouraged by the results of these initial studies for our LAMA/LABA, an important cornerstone of our broad respiratory development portfolio…. These studies, together with our earlier dose-ranging work, give us confidence that this is a once-daily medicine with the potential to benefit many patients with COPD.
It is hoped that this new investment in sustainable chemistry will help to further strengthen the UK as a leader in life-sciences while contributing to environmental stewardship.
The Chair will be responsible for developing and sharing best practice in green chemistry and catalysing new collaborations with other institutions and industry partners.
Sir Andrew Witty, CEO of GSK said: “We recognise that the success of the Sustainable Chemistry centre being established at the University of Nottingham will rely on the experts running it. That is why we are delighted to collaborate with EPSRC to jointly contribute to the funding of this new Chair. We hope this support will enable the University of Nottingham to attract a world class leader, helping to forge stronger links between industry and academia and encourage more young people into science.”
PharmPro reported that GlaxoSmithKline has announced that its Votrient (pazopanib) drug has been issued with a positive opinion by the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP).
Votrient® (pazopanib) will be used in the treatment of adult patients with selective subtypes of advanced Soft Tissue Sarcoma (STS) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo) adjuvant therapy.
As part of its assessment, the CHMP reviewed safety and efficacy data from clinical studies, including one randomised, double-blind, placebo controlled, multi-centre Phase III study.
This is good news for those who have selective subtypes of advanced Soft Tissue Sarcoma.
The Telegraph have reported that GSK today, announced that it has entered an agreement to acquire Cellzome for £61 million in which they already own a 20pc stake.
Cellzome is the leader in the development and advancement of proteomics technologies. It currently has labs in Cambridge in the UK and Heidelberg in Germany. GSK currently own 19.98 % equity in the company but they will now assume full control of Cellzome. It will become part of GSK’s R&D organisation.
John Baldoni, senior vice-president of Platform & Technology Science at Glaxo, said: “The acquisition of Cellzome adds significantly to our scientific capabilities and capacity to characterise drug targets, and provides the opportunity to further enhance Glaxo’s ability to bring medicines to patients in a more effective manner.”
GlaxoSmithKline and the University of Nottingham are to collaborate together to establish a new laboratory to accommodate the Centre of Excellence for sustainable chemistry and to construct an innovative carbon neutral sustainable chemistry laboratory.
The GlaxoSmithKline Carbon Neutral Laboratory for Sustainable Chemistry will be based on the University’s Jubilee Campus and its construction is being supported by a £12m grant from GSK
The focus on sustainability will be reflected in the building itself, which will incorporate the latest technologies to allow it to be carbon-neutral over its lifetime
Sir Andrew Witty, CEO of GSK said: “The carbon neutral laboratory will help affirm the UK as a global hub for the future of the life-sciences industry
BBC News have reported that GlaxoSmithKlinehave released a press statement today confirming that it will invest more than £500m in the UK across its manufacturing sites to increase production of key aspects for its pharmaceutical products and vaccines. This investment could create up to a 1000 new jobs.
GSK also announced a new manufacturing facility to be built in Ulverston in Cumbria. The biopharmaceutical facility will be its first new UK factory for 40 years.
Investment will also be made at the company’s two manufacturing sites in Scotland at Montrose and Irvine.
These investments represent one of the largest commitments to the UK life-sciences sector in recent years. They follow confirmation by the Government in the Budget yesterday that it will implement a ‘patent box’ to encourage investment in R&D and related manufacturing in the UK, by introducing a lower rate of corporation tax on profits generated from UK-owned intellectual property
Prime Minister David Cameron said: “This is excellent news, a major investment that will create many highly skilled jobs and provide a great boost to the economy….We have a world class life sciences industry, and I am determined not just to keep it here in the UK but significantly increase it too… Our innovative life sciences strategy and ground breaking patent box are already making a difference, helping to grow this important industry and ensure the great discoveries of the next decade happen here in British laboratories.
GSK Media Centre released a press statement announcing the launch of a new multi-disciplinary apprenticeship scheme. The programme, which will sit alongside GSK’s established graduate and undergraduate recruitment schemes, is aimed at 16-24 year olds and will offer positions at the company’s UK manufacturing, R&D and corporate sites.
The scheme will commence in August this year and GSK will take on 40 apprentices in the first intake. The apprenticeships will last between 2 and 4 years depending on which area it is in. There will be IT, R&D Laboratory Technician, Manufacturing, Supply Chain management and Artwork Design opportunities.
In addition to a competitive base salary, apprentices will benefit from a personalised training plan and a GSK mentor, who will provide advice and support over the duration of the programme. If there is an apprentice who demonstrates the skills and behaviour GSK is looking for, they will be offered a role with the company at the end of the programme
Natalie Woodford, SVP, Talent, Leadership & Organisation Development at GSK said: “GSK is committed to attracting and developing talent at all levels, and youth training and apprenticeships have a vital role in building the right skills our employees need for the future. We are delighted to announce this programme today, which will give young people hands-on experience in the life sciences industry; a key sector for the UK.”
The laboratory which is in Harlow, Essex will be operated by both scientists and leading experts from Kings College London. It will test 6, 250 samples throughout the duration of the Olympic and Paralympic Games, which is many more than have been tested in previous Games.
The new drug testing laboratory will employ over 1,000 staff to work within the anti-doping process, as well as 150 scientists who will carry out the testing. The team will be lead by Professor David Cowan from the Drug Control Centre at King’s College London. The laboratory will be in operation 24 hours a day, 7 days a week.
Sir Andrew Witty, CEO of GlaxoSmithKline, said: ‘As a science-based organisation, GSK is well placed to help deliver the scale and cutting edge technology required to run an operation like the anti-doping facility for London 2012.
‘We have worked with King’s to put systems in place to enable this laboratory to test more samples than any previous Games and at the same time developing a blueprint for doping operations at future Games.’
As reported by the BBC, the award, named The Queen Elizabeth Prize of Engineering, will be awarded every two years for outstanding advances in engineering. The prestigious award will be launched later today at London’s Science Museum.
The award, which will be awarded to teams of up to three people, and will be awarded by the Royal Academy of Engineering and overseen by Lord John Browne, former CEO of BP. The award will also be funded by companies such as BAE Systems, Shell and GlaxoSmithKline, Speaking of the award, Browne stated,
“Engineering underpins every aspect of our lives. As the bridge between scientific discovery and commercial application, engineering feeds and clothes us and enables us to work, travel and communicate.
“But too often the engineers behind the most brilliant innovations remain hidden. The Queen Elizabeth Prize aims to change that.”
It is hoped that the award will help boost the profile of engineering and help encourage more young people to consider it as a career path.
As Andrew Witty, CEO of GSK explains, the plan comes are a result of tax breaks on innovation introduced by Chancellor George Osbourne, ‘Because of changes in the UK tax regime, it will be our intention to bring more activity to Britain and take advantage of the situation here and increase our contribution to Britain. If it [corporation tax] is going to come down over the next few years, it will attract us to pay more tax here.’
The global pharma are considering Cumbria, County Durham and two locations in Scotland for their new factory. A decision is expected to be made in May.
At least three private equity firms are planning a bid for GSK non-prescription drugs, reports Reuters.
The products being bid for include over the counter painkillers and vitamin supplements. These sales are the product of GSK’s reduction of non-core products announced in February, representing 10% of the consumer healthcare business. Bids for the products are expected on 8th August, but will be negotiable. CEO Andrew Witty expects the deals to close in the fourth quarter of 2011 before adding that GSK will be looking for the best deal for shareholders to benefit.
Rival companies are unlikely to bid for all the products GSK is looking to offload, worth a maximum of around £2 billion. However because the products will not be sold as a single body, analysts believe that GSK will not be able to make that amount. The lack of coherence in the products on sale, other than, as one analyst says “stuff that GSK doesn’t want,” also means it will be difficult to sell the portfolio for such an amount in one go.
The investment is expected to create up to 1,000 jobs in one of four UK plants, with Montrose thought to be the front runner due to the recent movement of biomanufacturing of several products from India to the Montrose plant. The Montrose factory also manufactures the products needed to make products that GSK inherited following its acquisition of Steifel in 2009.
Andrew Witty, GSK chief executive, praised the 280 staff at the Montrose factory for turning around what was an ailing site, up for sale at the turn of the Millennium, into a “globally competitive” production plant.
There is some speculation that the global pharmaceutical company, GlaxoSmithKline, are planning to open their first new UK factory in 30 years, potentially creating 1,000 new pharmaceutical jobs.
Andrew Witty, chief executive of GSK is said to have not ruled out Montrose as a possible location for the new factory. The Montrose site current has 230 permanent and 50 part-time staff on it’s payroll.
Speaking of the Montrose site, Witty stated, “It is extraordinary to think that a few years ago the Montrose plant was close to shutting.
But the workforce applied great brain power to cost and process efficiently and now we are bringing work back from India – and Montrose is where it is going.
This is a workforce that has outmanoeuvred the threat of closure.”
Other sites shortlisted as possible locations for the new biopharmaceutical site include Barnard Castle, County Durham, Irvine and Ulverston.
As reported by The Telegraph, The global pharmaceutical company, GlaxoSmithKline (GSK), is to pay up to £27,000 university tuition fees for 50 to 100 of their graduate trainees. They are the first company to announce help recruits in this way.
The company’s chief executive, Andrew Witty announced the news on Sky News. He stated that the scheme was not restricted to scientists, chemists and pharmacists, but will also be available to lawyers, economists and all of the other top class graduates that could help the pharmaceutical company. He said, “The biggest reason we are doing this is that we want to get the absolute best possible graduates we can to work for GSK,” he told the programme. This is a great way for us to try and ensure we get that next brilliant scientist.”
As of next year, university tuition fees will triple for undergraduates so this is great news for budding scientists who are interested in working in the Pharmaceutical industry.
It is hoped that the announcement of GSK’s scheme will will encourage other companies to follow suit and help their recruits with crippling tuition fees. Thus ensuring that potential top talent will continue with their education.
GSK’s programme will costs them around £3 million per year and trainees will be required to stay with the company for several years until the fees have be repaid.
As reported by The Recruiter, the global pharmaceutical company GlaxoSmithKline will be recruiting British university students to work on the discovery of the drugs of the future.
The pharma company plans to launch a medicinal chemistry module using students in their third year of their Master of Science study at the University of Nottingham. The project will run over two terms with 12 students and will focus on research, synthesis and testing of PI 3 kinase inhibitors, which are currently under investigation by a number of drug companies. GSK will be researching their potential in the treatment of asthma.
The move comes as large pharmaceutical companies take steps to strengthen partnerships with academia in a bid to boost innovation in research whilst reducing costs.
The scheme will be a great opportunity for students to make a name for themselves as inventors of patents, with the possibility of receiving royalties if their work was translated into a successful drug.
Head of Chemistry at GSK, Dave Allen stated. “This is not a way of saving money, but we are not a charity and we get something back. Our people will mentor, and get a sense of innovation from students.”
CK Science is delighted to announce that the winner of our Temp Workers World Cup Sweepstake is Kate Lowe. Kate is currently temping at GlaxoSmithKline (GSK) and was delighted to win her £25.00 worth of Amazon vouchers from the CK Science team. Upon receiving her prize, Kate stated:
“All you footy fans out there will be horrified to learn that I don’t follow football at all, so was not really interested in the outcome of the World Cup….but being a woman, £25 to go shopping with is fab! I have added a few of my own pounds to the Amazon voucher and bought a ladybird house, ladybird larvae and some food for them, in the hope that they will munch their way through all greenfly so I can be a bit more environmentally friendly and stop using pesticides in my garden.”
Kate Lowe – CK Science Temp Workers World Cup Sweepstake Winner
As a temporary worker at CK Science, Kate also kindly gave a glowing report of her experience of working with CK Science. Kate said,
“Last September I was made redundant and sent my CV out to several scientific agencies, looking for immediate work. All rang me up within a day or two of receiving my CV. All of them promised quick results, but CK was the only agency to actually get me an interview….within four days of them receiving my CV I had not only been interviewed, but had a start date for my contract at GSK. I have been here nine months and just had my contract renewed for another six. I find CK to be proactive, friendly and helpful and they deal with any queries that I have promptly.”
Rhiannon Myers, one of our temporary workers at Merck was selected The Netherlands in the sweepstake, and thus won the second prize of £10.00 of Amazon vouchers. Well done Rhiannon, we hope you have fun spending!